A phase II dose-ranging study of mirabegron in patients with overactive bladder

被引：0
|
作者：
Christopher R. Chapple
Vladimir Dvorak
Pjotr Radziszewski
Philip Van Kerrebroeck
Jean Jacques Wyndaele
Brigitte Bosman
Peter Boerrigter
Ted Drogendijk
Arwin Ridder
Ingrid Van Der Putten-Slob
Osamu Yamaguchi
机构：
[1] Sheffield Teaching Hospitals,Department of Urology, Royal Hallamshire Hospital
[2] Centrum ambulantní gynekologie a primární péce,Department of Urology
[3] Medical University Warsaw,Department Urology
[4] Maastricht University Medical Center,Department of Urology
[5] Antwerp University and Antwerp University Hospital,Division of Bioengineering and LUTD Research, School of Engineering
[6] Astellas Pharma Europe BV,undefined
[7] Nihon University,undefined
来源：
International Urogynecology Journal | 2013年 / 24卷
关键词：
β; -adrenoceptor agonist; Mirabegron; Overactive; Urinary bladder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1447 / 1458
页数：11
相关论文
共 50 条
  • [21] Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
    Ito, Hidenori
    Matsuo, Tomohiro
    Mitsunari, Kensuke
    Ohba, Kojiro
    Miyata, Yasuyoshi
    MEDICINA-LITHUANIA, 2022, 58 (06):
  • [22] Comparison of the efficacy and safety of onabotulinum toxin A and mirabegron for overactive bladder in elderly patients
    Karakeci, A.
    Keles, A.
    Onur, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2024, 28 (01) : 350 - 356
  • [23] How durable is the effect of mirabegron in successfully-treated overactive bladder patients? Analysis of a multicentre study
    Svabik, K.
    Masata, J.
    Krhut, J.
    Zachoval, R.
    Hanus, T.
    Halaska, M.
    Martan, A.
    CESKA GYNEKOLOGIE-CZECH GYNAECOLOGY, 2018, 83 (03): : 164 - 168
  • [24] Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study
    Gibson, William
    MacDiarmid, Scott
    Huang, Moses
    Siddiqui, Emad
    Stolzel, Matthias
    Choudhury, Nurul
    Drake, Marcus J.
    EUROPEAN UROLOGY FOCUS, 2017, 3 (06): : 629 - 638
  • [25] Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study
    Martan, Alois
    Masata, Jaromir
    Krhut, Jan
    Zachoval, Roman
    Hanus, Tomas
    Svabik, Kamil
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 210 : 247 - 250
  • [26] Effect of Mirabegron in Men With Overactive Bladder and Erectile Dysfunction: A Prospective Observational Study
    Singh, Rana P.
    Jamal, Arshad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [27] Efficacy and Safety of Low Doses of OnabotulinumtoxinA for the Treatment of Refractory Idiopathic Overactive Bladder: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Dose-Ranging Study
    Denys, Pierre
    Le Normand, Loic
    Ghout, Idir
    Costa, Pierre
    Chartier-Kastler, Emmanuel
    Grise, Philippe
    Hermieu, Jean-Francois
    Amarenco, Gerard
    Karsenty, Gilles
    Saussine, Christian
    Barbot, Frederic
    EUROPEAN UROLOGY, 2012, 61 (03) : 520 - 529
  • [28] Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy
    MacDiarmid, Scott
    Al-Shukri, Salman
    Barkin, Jack
    Fianu-Jonasson, Aino
    Grise, Philippe
    Herschorn, Sender
    Saleem, Tahir
    Huang, Moses
    Siddiqui, Emad
    Stolzel, Matthias
    Hemsted, Claire
    Nazir, Jameel
    Hakimi, Zalmai
    Drake, Marcus J.
    JOURNAL OF UROLOGY, 2016, 196 (03) : 809 - 818
  • [29] The efficacy and tolerability of mirabegron, a beta 3 adrenoceptor agonist, in patients with symptoms of overactive bladder
    Thiagamoorthy, Ganesh
    Kotes, Stephanie
    Zacche, Martino
    Cardozo, Linda
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (01) : 38 - 46
  • [30] Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?
    Manami Kinjo
    Kazuki Masuda
    Yu Nakamura
    Satoru Taguchi
    Mitsuhiro Tambo
    Hiroshi Fukuhara
    International Urogynecology Journal, 2023, 34 : 853 - 859
12345